trending Market Intelligence /marketintelligence/en/news-insights/trending/IBo7ouQJUYp0ZtTzsQNWrw2 content esgSubNav
In This List

Allergan, Richter bipolar depression drug meets main goal in phase 3 study

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


Allergan, Richter bipolar depression drug meets main goal in phase 3 study

Allergan plc and Gedeon Richter Plc said the phase 3 trial of Vraylar for treating major depressive episodes associated with bipolar 1 depression met its main goal.

Results from the RGH-MD-54 study showed that the 1.5- and 3-milligram doses of the treatment, also known as cariprazine, worked better than placebo.

Vraylar was also well tolerated under the study.

Allergan plans to submit a supplemental new drug application to expand Vraylar's indication in the U.S., in the second half of 2018.

Vraylar was discovered and co-developed by Gedeon Richter and is licensed by Allergan in the U.S. and Canada.

Vraylar is already approved as a treatment of adult patients with manic or mixed episodes associated with bipolar 1 disorder as well as for adults with schizophrenia.